Mizuho’s Salim Syed highlights 24% upside potential for BIIB shares, noting most investors were bracing themselves for this Phase II failure.
Maxim’s Jason Kolbert bets AEZS’ oral test could set a new standard in addressing Adult Growth Hormone Deficiency (AGHD) with FDA approval now under its belt.
Bioline RX Ltd (NASDAQ:BLRX) is officially turning its Phase 3 GENESES clinical trial’s wheels, with the Israeli drug maker revealing today the launch …
Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold or wins the regulator’s bless. …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced that its affiliate has completed the divestiture of the Sprout Pharmaceuticals subsidiary to Sprout2 Inc., an entity …
Galectin Therapeutics Inc (NASDAQ:GALT) shares are jumping almost 18% today on the heels of the drug maker walking into a credit line to …
Exelixis, Inc. (NASDAQ:EXEL) said on Tuesday that the FDA approved its CABOMETYX tablets, for the expanded indication of patients with advanced renal cell carcinoma …
Cantor’s William Tanner is not thrilled as he joins a disgruntled Street saying goodbye to what could have been a meaningful catalyst for NVAX shares before the end of 2017: NanoFlu vaccine top-line data.
Is Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) “a ticking bomb” after new Danish CEO Kare Schultz has ordered a quarter of the Israeli …
Shares in innovative biopharma Synergy Pharmaceuticals Inc (NASDAQ:SGYP) are rising 3% to $2.06 in today’s trading on the news that the company has …
